Aminoglycosides Market Report 2026

The aminoglycosides market size has grown strongly in recent years. It will grow from $1.91 billion in 2025 to $2.02 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to high incidence of abdominal and urinary tract infections, widespread use of broad-spectrum antibiotics, conventional manufacturing processes, limited regulatory oversight in veterinary applications, strong demand in ophthalmic solutions.

The aminoglycosides market size is expected to see strong growth in the next few years. It will grow to $2.56 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to increased r&d in targeted aminoglycoside therapies, rising awareness of antibiotic resistance, adoption of advanced drug delivery systems, expansion of veterinary healthcare market, growth in personalized medicine applications. Major trends in the forecast period include rising prevalence of gram-negative infections, increased veterinary use of aminoglycosides, development of novel aminoglycoside derivatives, shift towards injectable and targeted formulations, expansion of ophthalmic and inhalation applications.

The increasing incidence of animal disease outbreaks is a key factor expected to drive the growth of the aminoglycosides market in the coming years. An animal disease is defined as a condition that disrupts the normal health status of an animal by impairing or altering its vital functions. Aminoglycosides, such as amikacin and gentamicin, are among the most frequently used antibiotics in veterinary medicine. For example, in July 2025, according to GOV.UK, a UK-based government agency, laboratory-confirmed cases of leptospirosis in England rose from 70 in 2023 to 102 in 2024, marking an increase of 45.7%. Additionally, 890 cases of pasteurellosis were reported in 2024, compared to 815 cases in 2023. Therefore, the growing frequency of animal disease outbreaks is expected to continue driving the aminoglycosides market.

The rise in pet ownership is anticipated to drive the growth of the aminoglycosides market in the coming years. Pet ownership refers to the practice of keeping and caring for animals, commonly known as pets, within a household or living environment. Growing pet ownership supports the aminoglycosides market by expanding the customer base, promoting a culture of preventive healthcare for pets, and encouraging increased investment in veterinary pharmaceuticals to meet the varied health needs of companion animals. For example, in March 2023, according to Improve International, a US-based veterinary educational resource, there were 38 million pets across 16.2 million UK households, representing approximately 57% of all households. Therefore, the increase in pet ownership is contributing to the growth of the aminoglycosides market.

Major companies operating in the aminoglycosides market are concentrating on developing innovative solutions, including advanced manufacturing techniques and improved formulation processes, to address the growing demand for high-efficacy, next-generation antibiotics capable of treating resistant bacterial infections. These process enhancements improve purity, stability, and therapeutic effectiveness compared with conventional aminoglycoside production methods. For example, in February 2024, Cipla Limited, an India-based pharmaceutical company, received approval from the Central Drugs Standard Control Organization (CDSCO) for ZEMDRI (plazomicin), an intravenous aminoglycoside antibiotic, in India. This drug is specifically indicated for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis.

Major companies operating in the aminoglycosides market are Kremoint Pharma Pvt. Ltd., Vega Pharma Ltd., Jiangxi Bolai Pharmacy Co. Ltd., Xian Wison Biological Technology Co. Ltd., Hangzhou Uniwise International Co. Ltd., HuvePharma Inc., Yi Chang Veterinary Medicine Factory, Medson Pharmaceuticals, Medico Remedies Pvt. Ltd., Cipla Limited, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Zoetis Inc., Novartis AG, Johnson & Johnson Inc., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Zydus Lifescience Limited, Lupin Limited, Aurobindo Pharma Limited, Fresenius Kabi AG, Aspen Pharmacare Holdings Limited, Mylan N.V., Sanofi SA, Wyeth Pharmaceuticals Inc., Zhejiang Hisun Pharmaceutical Co. Ltd., GlaxoSmithKline plc, Allergan PLC, Bristol Myers Squibb Company.

Asia-Pacific was the largest region in the aminoglycosides market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the aminoglycosides market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the aminoglycosides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the aminoglycosides market by increasing the cost of imported raw materials and active pharmaceutical ingredients (APIs), thereby affecting manufacturing and pricing strategies. Injectable and oral formulations are particularly impacted, with Asia-Pacific regions, such as India and China, facing higher cost pressures due to import dependencies. While tariffs pose challenges, they have encouraged local manufacturing investments and innovation in derivative therapies, creating opportunities for cost optimization and self-reliant supply chains in North America and Europe.

The aminoglycosides market research report is one of a series of new reports that provides aminoglycosides market statistics, including aminoglycosides industry global market size, regional shares, competitors with a aminoglycosides market share, detailed aminoglycosides market segments, market trends and opportunities, and any further data you may need to thrive in the aminoglycosides industry. This aminoglycosides market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Aminoglycosides are a class of antibiotics that inhibit protein synthesis. They are used in the treatment of aerobic gram-negative bacilli infections of the abdomen and urinary tract, as well as bacteremia and endocarditis.

The main aminoglycoside products include neomycin, tobramycin, gentamicin, amikacin, paromomycin, streptomycin, kanamycin, and others. Neomycin is used to prevent bacterial infections in the intestines. It is a broad-spectrum aminoglycoside antibiotic derived from the metabolic products of Streptomyces fradiae. The routes of administration for aminoglycosides include injectable (parenteral), feed, intramammary, topical, and oral forms, and they are applied in veterinary use, skin infections, respiratory diseases, urinary tract and pelvic diseases, as well as other conditions.

The aminoglycosides market consists of sales of plazomicin and netilmicin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.